Canfield P, Coruzzi G, Curwain B, Rundell T
Eur J Pharmacol. 1985 Oct 8;116(1-2):89-95. doi: 10.1016/0014-2999(85)90188-8.
The actions of two mast cell stabilising agents, FPL 52694 and disodium cromoglycate and the Ca2+ channel antagonist verapamil on acid secretion by the rat isolated stomach have been studied. FPL 52694 (1-5 mM) in the serosal medium stimulated acid secretion. This was antagonised by prostaglandin E2 but not by atropine, metiamide, propranolol or tetrodotoxin. FPL 52694 (1-5 mM) in the mucosal medium had an inhibitory effect on basal acid secretion and that stimulated by pentagastrin and histamine. The inhibition reversed only slowly after removal of FPL 52694. Disodium cromoglycate and serosal application of verapamil had no significant effects on acid output. Removal of calcium from the bathing solutions and mucosal verapamil inhibited basal secretion. Topically applied, FPL 52694 is a potent inhibitor of acid secretion in vitro. This effect may involve an action upon the availability of calcium to the tissue. The stimulatory effects of serosal FPL 52694 are discussed in relation to previous in vivo findings.
研究了两种肥大细胞稳定剂FPL 52694和色甘酸钠以及钙通道拮抗剂维拉帕米对大鼠离体胃泌酸的作用。浆膜介质中的FPL 52694(1 - 5 mM)刺激胃酸分泌。这种作用被前列腺素E2拮抗,但不受阿托品、甲硫咪特、普萘洛尔或河豚毒素拮抗。粘膜介质中的FPL 52694(1 - 5 mM)对基础胃酸分泌以及五肽胃泌素和组胺刺激的胃酸分泌有抑制作用。去除FPL 52694后,抑制作用仅缓慢逆转。色甘酸钠和浆膜应用维拉帕米对胃酸分泌无显著影响。从浴液中去除钙和粘膜应用维拉帕米抑制基础分泌。局部应用时,FPL 52694在体外是一种有效的胃酸分泌抑制剂。这种作用可能涉及对组织钙可用性的影响。结合先前的体内研究结果讨论了浆膜FPL 52694的刺激作用。